Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2017 | Pages:
365 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Malaria - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malaria - Pipeline Review, H1 2017, provides an overview of the Malaria (Infectious Disease) pipeline landscape. Malaria is a life-threatening blood disease caused by a parasite (Plasmodium) that is transmitted to humans by the Anopheles mosquito. People at increased risk of serious disease include young children and infants, travelers coming from areas with no malaria and pregnant women and their unborn children. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea and vomiting. Treatment includes anti-malarial medicines and healthy lifestyle. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malaria - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Malaria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Malaria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Malaria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 12, 10, 55 and 31 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 3, 11, 45 and 41 molecules, respectively. Malaria (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Malaria (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Malaria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Malaria (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Malaria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Malaria (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Malaria (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Malaria (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 5 Malaria - Overview 6 Malaria - Therapeutics Development 7 Malaria - Therapeutics Assessment 30 Malaria - Companies Involved in Therapeutics Development 41 Malaria - Drug Profiles 69 Malaria - Dormant Projects 319 Malaria - Discontinued Products 327 Malaria - Product Development Milestones 329 Appendix 344
List of Tables
Number of Products under Development for Malaria, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Products under Development by Companies, H1 2017 (Contd..5), H1 2017 Products under Development by Universities/Institutes, H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..5), H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Malaria - Pipeline by 4SC AG, H1 2017 Malaria - Pipeline by Actelion Ltd, H1 2017 Malaria - Pipeline by Agilvax Inc, H1 2017 Malaria - Pipeline by Akshaya Bio Inc, H1 2017 Malaria - Pipeline by Alfa Wassermann SpA, H1 2017 Malaria - Pipeline by Allergy Therapeutics Plc, H1 2017 Malaria - Pipeline by Altimmune Inc, H1 2017 Malaria - Pipeline by Amura Holdings Ltd, H1 2017 Malaria - Pipeline by Anacor Pharmaceuticals Inc, H1 2017 Malaria - Pipeline by Artificial Cell Technologies Inc, H1 2017 Malaria - Pipeline by AstraZeneca Plc, H1 2017 Malaria - Pipeline by Atreca Inc, H1 2017 Malaria - Pipeline by Bharat Biotech International Ltd, H1 2017 Malaria - Pipeline by Carna Biosciences Inc, H1 2017 Malaria - Pipeline by CEL-SCI Corp, H1 2017 Malaria - Pipeline by Celgene Corp, H1 2017 Malaria - Pipeline by Cilian AG, H1 2017 Malaria - Pipeline by Daiichi Sankyo Company Ltd, H1 2017 Malaria - Pipeline by DesignMedix Inc, H1 2017 Malaria - Pipeline by Eisai Co Ltd, H1 2017 Malaria - Pipeline by GenVec Inc, H1 2017 Malaria - Pipeline by Genzyme Corp, H1 2017 Malaria - Pipeline by GeoVax Labs Inc, H1 2017 Malaria - Pipeline by GlaxoSmithKline Plc, H1 2017 Malaria - Pipeline by Griffith University, H1 2017 Malaria - Pipeline by Hager Biosciences LLC, H1 2017 Malaria - Pipeline by iBio Inc, H1 2017 Malaria - Pipeline by Ichor Medical Systems Inc, H1 2017 Malaria - Pipeline by Imaxio SA, H1 2017 Malaria - Pipeline by Immtech Pharmaceuticals Inc, H1 2017 Malaria - Pipeline by Immunovaccine Inc, H1 2017 Malaria - Pipeline by IPCA Laboratories Ltd, H1 2017 Malaria - Pipeline by IRBM Science Park SpA, H1 2017 Malaria - Pipeline by Jenrin Discovery Inc, H1 2017 Malaria - Pipeline by Jomaa Pharma GmbH, H1 2017 Malaria - Pipeline by Kancera AB, H1 2017 Malaria - Pipeline by Kymab Ltd, H1 2017 Malaria - Pipeline by Lipocure Ltd, H1 2017 Malaria - Pipeline by Lipotek Pty Ltd, H1 2017 Malaria - Pipeline by LondonPharma Ltd, H1 2017 Malaria - Pipeline by Marinomed Biotechnologie GmbH, H1 2017 Malaria - Pipeline by Merck & Co Inc, H1 2017 Malaria - Pipeline by Merck KGaA, H1 2017 Malaria - Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2017 Malaria - Pipeline by Microbiotix Inc, H1 2017 Malaria - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017 Malaria - Pipeline by Mucosis BV, H1 2017 Malaria - Pipeline by Mymetics Corp, H1 2017 Malaria - Pipeline by Novartis AG, H1 2017 Malaria - Pipeline by PaxVax Inc, H1 2017 Malaria - Pipeline by Pfizer Inc, H1 2017 Malaria - Pipeline by Protein Potential LLC, H1 2017 Malaria - Pipeline by Rodos BioTarget GmbH, H1 2017 Malaria - Pipeline by Sanaria Inc, H1 2017 Malaria - Pipeline by Sanofi, H1 2017 Malaria - Pipeline by SBI Pharmaceuticals Co Ltd, H1 2017 Malaria - Pipeline by Selecta Biosciences Inc, H1 2017 Malaria - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017 Malaria - Pipeline by Theravectys SA, H1 2017 Malaria - Pipeline by Tomegavax Inc, H1 2017 Malaria - Pipeline by Toyama Chemical Co Ltd, H1 2017 Malaria - Pipeline by VLP Biotech Inc, H1 2017 Malaria - Pipeline by VLP Therapeutics LLC, H1 2017 Malaria - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017 Malaria - Dormant Projects, H1 2017 Malaria - Dormant Projects, H1 2017 (Contd..1), H1 2017 Malaria - Dormant Projects, H1 2017 (Contd..2), H1 2017 Malaria - Dormant Projects, H1 2017 (Contd..3), H1 2017 Malaria - Dormant Projects, H1 2017 (Contd..4), H1 2017 Malaria - Dormant Projects, H1 2017 (Contd..5), H1 2017 Malaria - Dormant Projects, H1 2017 (Contd..6), H1 2017 Malaria - Dormant Projects, H1 2017 (Contd..7), H1 2017 Malaria - Discontinued Products, H1 2017 Malaria - Discontinued Products, H1 2017 (Contd..1), H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
